Genetronics Biomedical Corporation

February 25, 2005 10:12 ET

Genetronics' President and CEO to Present at Wells Fargo's 2005 Healthcare Conference




FEBRUARY 25, 2005 - 10:12 ET

Genetronics' President and CEO to Present at Wells
Fargo's 2005 Healthcare Conference

SAN DIEGO--(CCNMatthews - Feb 25, 2005) -

Genetronics Biomedical Corporation (AMEX:GEB), a late stage developer of
oncology and other therapies using electroporation to deliver drugs and
nucleic acids, announced today that Avtar Dhillon, MD, President and
CEO, will present a corporate overview on the Company at Wells Fargo
Securities' 2005 Healthcare Conference on Tuesday, March 1 at 9:30 a.m.
Eastern Standard Time (6:30 a.m. PST). The conference will be held at
the St. Regis in New York City from March 1 - 2.

A live webcast of the presentation, including slides, will be available
on the Company's website at and will be archived
there for 30 days following the conclusion of the broadcast. Please
connect to Genetronics' website several minutes prior to the start of
the webcast to ensure adequate time for any software download that may
be necessary.

About Genetronics Biomedical Corporation

Genetronics Biomedical Corporation is a late stage biomedical company
focused on building an oncology franchise based on its proprietary
electroporation therapy. The therapy targets a significant unmet
clinical need: the selective killing of cancer cells and local ablation
of solid tumors while preserving healthy tissue. The company is moving
its lead product, the MedPulser® Electroporation Therapy System,
through pre-marketing studies for head and neck cancer and skin cancer
in Europe, where it has CE Mark accreditation, and a U.S. Phase III
pivotal study for recurrent head and neck cancer. Merck, Vical, Chiron,
the U.S. Navy, and other partners are employing Genetronics'
electroporation technology, which enhances local delivery and cellular
uptake of useful biopharmaceuticals, in their development of novel DNA
vaccines and gene therapies. Genetronics is a leader in electroporation,
with over 240 patents worldwide that are issued, allowed or pending.
More information can be obtained at

This press release contains certain forward-looking statements relating
to Genetronics' plans to develop its electroporation drug and gene
delivery technology and to maximize shareholder value. Actual events or
results may differ from Genetronics' expectations as a result of a
number of factors, including the uncertainties inherent in clinical
trials and product development programs, evaluation of potential
opportunities, the level of corporate expenditures, the assessment of
Genetronics' technology by potential corporate partners, and capital
market conditions, and others set forth in the Genetronics Annual
Report, on Form 10-K for the 12-month period ended December 31, 2003,
and the Form 10-Q for the 9-month period ended September 30, 2004, and
other regulatory filings. There can be no assurance that any product in
the Genetronics product pipeline will be successfully developed or
manufactured, or that final results of human pilot studies or clinical
studies will be supportive of regulatory approvals required to market
licensed products.


Contact Information

    Genetronics Biomedical Corporation
    Bernie Hertel, 858-410-3101
    Investor Relations
    Atkins + Associates
    Rebecca Wong, 858-527-3495
    Media Relations